Eton Pharmaceuticals, Inc. - 10-Q Filing
Eton Pharmaceuticals reports Q3 2026 financial results including updates on Impavido licensing and Selenix DS200 agreements.
Tickers: $ETON
Read the full article at SEC EDGAR
Part of the story Eton Pharmaceuticals, Inc. - 10-Q Filing (3 articles)